公开(公告)号：US20090042279A1

公开(公告)日：2009-02-12

申请号：US12248876

申请日：2008-10-09

申请人： Masaru YAMAKOSHI ,  Takuji Kouzuma

发明人： Masaru YAMAKOSHI ,  Takuji Kouzuma

IPC分类号： C12P1/00

CPC分类号： C12Q1/32 ,  C12Q1/485 ,  C12Q1/54 ,  G01N33/66 ,  G01N33/6893 ,  G01N2800/042

摘要： It is intended to provide a noninvasive method of conveniently detecting mild impaired glucose tolerance and/or insulin hyposecretion at the early stage with the use of an enzyme. Namely, mild impaired glucose tolerance and/or insulin hyposecretion at the early stage are detected by quantifying myoinositol secreted into the urine before loading glucose and after loading glucose for a definite period of time with the use of a reagent and comparing the increase (or the increase ratio) in the myoinositol content thus measured with a characteristic level which has been preliminarily determined in normal subjects.

摘要翻译： 旨在提供一种在使用酶的早期方便地检测轻度葡萄糖耐量降低和/或胰岛素分泌不足的非侵入性方法。 即，通过在加载葡萄糖之前和在使用试剂加载葡萄糖一定时间后，通过量化分泌到尿液中的肌醇来检测早期的葡萄糖耐量降低和/或胰岛素分泌不足，并比较增加（或 增加比例）在由正常受试者预先确定的特征水平测量的肌醇含量中。

公开(公告)号：US20080319083A1

公开(公告)日：2008-12-25

申请号：US12109450

申请日：2008-04-25

申请人： Hideshi NATSUME

发明人： Hideshi NATSUME

IPC分类号： A61K31/165 ,  A61P29/00 ,  A61P25/24

CPC分类号： A61K31/165

摘要： The object is to provide an SNRI-containing preparation which has a higher absorbability compared to a conventional SNRI preparation, produces its effect rapidly, and is readily administered to a patient who is hard to be administered via an oral route.Disclosed is a preparation for transmucosal administration, comprising a selective serotonin/noradrenaline reuptake inhibitor and a thickening agent.

摘要翻译： 本发明的目的是提供一种与常规SNRI制剂相比具有较高吸收能力的含SNRI的制剂，其快速产生其效果，并且容易地施用于难以通过口服途径施用的患者。 公开了一种经粘膜给药的制剂，其包含选择性5-羟色胺/去甲肾上腺素再摄取抑制剂和增稠剂。

公开(公告)号：US20080295259A1

公开(公告)日：2008-12-04

申请号：US12034793

申请日：2008-02-21

申请人： Shigeru UEDA ,  Takeshi MATSUOKA ,  Akihiko KAN

发明人： Shigeru UEDA ,  Takeshi MATSUOKA ,  Akihiko KAN

IPC分类号： C09B67/00

CPC分类号： C12Q1/28 ,  C09B67/0077

摘要： Provided are a method of stabilizing a leuco dye storable as a liquid for a long time, a method of reducing nonspecific color development thereof at a time of a color development reaction, and a stable liquid reagent composition using the methods. The inventors of the present invention found that coexistence of the leuco dye with a specific reducing agent resulted in suppression of self color development and its remarkably improved stability in a solution, and that when a color development reaction of the leuco dye with hydrogen peroxide was performed, coexistence of the leuco dye, in a reaction solution, with another dye which had an absorption spectrum not influencing a measurement wavelength of the leuco dye and did not react with hydrogen peroxide suppressed nonspecific color development and lowered a reagent blank value, which was applied to an analytical reagent.

摘要翻译： 提供一种稳定长时间保存为液体的无色染料的方法，在显色反应时减少其非特异性显色的方法和使用该方法的稳定的液体试剂组合物。 本发明人发现，无色染料与特定的还原剂共存导致自色显影的抑制和其在溶液中的显着提高的稳定性，并且当进行无色染料与过氧化氢的显色反应时 在无色染料的反应溶液中与另一种不影响无色染料的测定波长的吸收光谱并且不与过氧化氢反应的染料共存抑制非特异性显色，降低试剂空白值 分析试剂。

公开(公告)号：US07452687B2

公开(公告)日：2008-11-18

申请号：US10509120

申请日：2003-03-27

申请人： Masaru Yamakoshi ,  Takuji Kouzuma

发明人： Masaru Yamakoshi ,  Takuji Kouzuma

IPC分类号： C12Q1/48 ,  C07C35/16

CPC分类号： C12Q1/32 ,  C12Q1/485 ,  C12Q1/54 ,  G01N33/66 ,  G01N33/6893 ,  G01N2800/042

摘要： It is intended to provide a noninvasive method of conveniently detecting mild impaired glucose tolerance and/or insulin hyposecretion at the early stage with the use of an enzyme. Namely, mild impaired glucose tolerance and/or hyposecretion at the early stage are detected by quantifying myoinositol secreted into the urine before loading glucose and after loading glucose for a definite period of time with the use of a reagent and comparing the increase (or the increase ratio) in the myoinositol content thus measured with a characteristic level which has been preliminarily determined in normal subjects.

摘要翻译： 旨在提供一种在使用酶的早期方便地检测轻度葡萄糖耐量降低和/或胰岛素分泌不足的非侵入性方法。 即，通过在加载葡萄糖之前和在使用试剂加载葡萄糖一定时间后，将分泌到尿液中的肌醇定量分析来检测早期的葡萄糖耐量降低和/或分泌不足，并比较增加（或增加 比例）在由正常受试者预先确定的特征水平测量的肌醇含量中。

公开(公告)号：US20080234483A1

公开(公告)日：2008-09-25

申请号：US10598303

申请日：2005-03-04

申请人： Takuji Maejima ,  Miki Ohshima

发明人： Takuji Maejima ,  Miki Ohshima

IPC分类号： C07D401/02

CPC分类号： A61K9/0019 ,  A61K31/551 ,  A61K47/02 ,  C07D401/12

摘要： Fasudil-containing preparations that despite the us of a container excelling in the visibility of contents without particularly blocking of light, exhibit high stability against light; and a method of improving the stability of the preparations against light of storing the same. By regulating the pH value of aqueous solution of fasudil charged in a colorless transparent container to ≦5.5, there can be provided fasudil-containing preparations excelling in stability against light; and can be provided a method of improving the stability of the aqueous solution of fasudil against light, or storing the same.

摘要翻译： 含法舒地尔的制剂，尽管我们的容器具有优异的内容物的可视性，而没有特别阻挡光，表现出高的光稳定性; 以及提高制剂的光稳定性的方法。 通过调节装在无色透明容器中的法舒地尔水溶液的pH值为<= 5.5，可以提供具有优异光稳定性的法舒地尔制剂。 并且可以提供一种改善法舒地尔的水溶液对光的稳定性或存储法舒地尔的方法。

公开(公告)号：US07312208B2

公开(公告)日：2007-12-25

申请号：US10647455

申请日：2003-08-26

申请人： Takehiko Sasahara ,  Mitsunobu Mohri

发明人： Takehiko Sasahara ,  Mitsunobu Mohri

IPC分类号： A61P9/00 ,  A61K31/553 ,  A61K31/554 ,  C07D281/10 ,  C07D513/02

CPC分类号： C07D281/10 ,  C07D453/02

摘要： Drugs useful for the treatment and prevention of hyperlipidemia, moreover drugs useful for the treatment and prevention of cholestasis-caused hepatopathy, particularly primary biliary cirrhosis and primary sclerosing cholangitis, and drugs for the treatment and prevention of obesity, fatty liver and steatohepatitis, containing as active ingredients benzothiazepine compounds having a thioamide bond and a quaternary ammonium substituent, represented by formula (1) below are provided. Also, drugs containing ileal bile acid transporter inhibiting compounds as active ingredients for the treatment and prevention of cholestasis-caused hepatopathy are provided.

摘要翻译： 用于治疗和预防高脂血症的药物，以及可用于治疗和预防胆汁淤积引起的肝病，特别是原发性胆汁性肝硬化和原发性硬化性胆管炎的药物，以及用于治疗和预防肥胖，脂肪肝和脂肪性肝炎的药物，其含有 提供了由下式（1）表示的具有硫代酰胺键和季铵取代基的活性成分苯并硫氮杂化合物。 此外，提供了含有回肠胆汁酸转运蛋白抑制化合物作为治疗和预防胆汁淤积引起的肝病的活性成分的药物。

公开(公告)号：US20070203115A1

公开(公告)日：2007-08-30

申请号：US11790975

申请日：2007-04-30

申请人： Takehiko Sasahara ,  Mitsunobu Mohri

发明人： Takehiko Sasahara ,  Mitsunobu Mohri

IPC分类号： A61K31/554

CPC分类号： C07D281/10 ,  C07D453/02

摘要： A method for inhibiting ileal bile acid transporter activity in a subject, comprising administering to said subject an effective amount of a compound represented by formula (1):

摘要翻译： 一种抑制受试者中回肠胆汁酸转运蛋白活性的方法，包括向所述受试者施用有效量的由式（1）表示的化合物：

公开(公告)号：US20240124859A1

公开(公告)日：2024-04-18

申请号：US18277967

申请日：2022-02-18

申请人： NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY ,  ASAHI KASEI PHARMA CORPORATION

发明人： Keitaro YOSHIDA ,  Yoshiaki YASUTAKE ,  Tomohiro TAMURA ,  Kenji KONISHI ,  Shin-ichi SAKASEGAWA ,  Shuji MURAMATSU

IPC分类号： C12N9/18 ,  C12N15/74

CPC分类号： C12N9/18 ,  C12N15/74 ,  C12Y301/01013

摘要： A method for producing a protein encoded by a target gene, comprising the step of



expressing the target gene in a bacterium of the genus Burkholderia, wherein the bacterium lacks one or more genes selected from the group consisting of BSFP_068740, BSFP_068730, and BSFP_068720, or has inhibited expression of the genes or proteins encoded by the genes.

公开(公告)号：US20240025893A1

公开(公告)日：2024-01-25

申请号：US18029289

申请日：2020-09-30

申请人： Asahi Kasei Pharma Corporation ,  Vernalis (R&D) Limited

发明人： Koichiro ARAI ,  Kenichiro TAKABA ,  Masakazu ATOBE ,  Misato TAKASHIMA ,  Naomi AONO ,  Andrew John POTTER ,  Daniel Paul MADDOX

IPC分类号： C07D471/04 ,  C07D417/08 ,  C07D417/14 ,  C07D498/18 ,  C07D491/107 ,  A61P35/02 ,  A61P19/02

CPC分类号： C07D471/04 ,  C07D417/08 ,  C07D417/14 ,  A61P19/02 ,  C07D491/107 ,  A61P35/02 ,  C07D498/18

摘要： A compound represented by the general formula (1) or a salt thereof, which has a superior IRAK-4 inhibitory activity, and is useful as active ingredients of medicaments for prophylactic treatment and/or therapeutic treatment of diseases relating to IRAK-4 inhibition.

公开(公告)号：US20230149382A1

公开(公告)日：2023-05-18

申请号：US17871423

申请日：2022-07-22

申请人： RaQualia Pharma Inc. ,  Asahi Kasei Pharma Corporation

发明人： Hirohide NOGUCHI ,  Yoshimasa ARANO ,  Kazuo ANDO ,  Kazuki TOYOSHIMA ,  Toshihiko SONE ,  Koki MATSUBARA

IPC分类号： A61K31/47 ,  C07D215/06

CPC分类号： A61K31/47 ,  C07D215/06

摘要： The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.